The selective serotonin reuptake inhibitor sertraline enhances counterregulatory responses to hypoglycemia

American Journal of Physiology - Endocrinology and Metabolism

Volumn 294, Issue 5, 2008, Pages

  Sanders, Nicole M ^a,d   Wilkinson, Charles W ^a,b   Taborsky Jr , Gerald J ^a   Al Noori, Salwa ^a,c   Daumen, Wendi ^c   Zavosh, Aryana ^c   Figlewicz, Dianne P ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Seattle Institute for Biomedical and Clinical Research   (United States)

^d VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Adrenomedullary; Epinephrine; Hypoglycemia associated autonomic failure

Indexed keywords

ADRENALIN; CORTICOSTERONE; CORTICOTROPIN; GLUCAGON; NORADRENALIN; SERTRALINE; SEROTONIN UPTAKE INHIBITOR;

ADRENAL MEDULLA; ANIMAL EXPERIMENT; ARTICLE; AUTONOMIC DYSFUNCTION; CONTROLLED STUDY; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HORMONAL REGULATION; HYPOGLYCEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; AUTONOMIC NERVOUS SYSTEM; BLOOD; BODY WEIGHT; DRUG EFFECT; EATING; METABOLISM; NEUROSECRETION; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; STIMULATION;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; AUTONOMIC NERVOUS SYSTEM; BLOOD GLUCOSE; BODY WEIGHT; CORTICOSTERONE; EATING; EPINEPHRINE; GLUCAGON; HYPOGLYCEMIA; MALE; NEUROSECRETORY SYSTEMS; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; STIMULATION, CHEMICAL;

EID: 45549103987     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00772.2007     Document Type: Article

References (50)

1. No authors listed. The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Study Group. N Engl J Med 329: 977-986, 1993.
2. Andrew SF, Dinh TT, Ritter S. Localized glucoprivation of hindbrain sites elicits corticosterone and glucagon secretion. Am J Physiol Regul Integr Comp Physiol 292: R1792-R1798, 2007.
3. Aunis D, Langley K. Physiological aspects of exocytosis in chromaffin cells in the adrenal medulla. Acta Physiol Scand: 89-97, 1999.
4. Bagdy G, Calogero A, Murphy D, Szemeredi K. Serotonin agonists cause parallel activation of the sympathoadrenomedullary system and the hypothalamo-pituitary-adrenocortical axis in conscious rats. Endocrinology 125: 2664-2669, 1989.
5. Benmansour S, Cecchi M, Morilak D, Gerhardt G, Javors M, Gould G, Frazer A. Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J Neurosci 19: 10494-10501, 1999.
6. Benmansour S, Owens WA, Cecchi M, Morilak DA, Frazer A. Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. J Neurosci 22: 6766-6772, 2002.
7. Blakely RD, Berson HE, Fremeau RT Jr, Caron MG, Peek MM, Prince HK, Bradley CC. Molecular cloning and functional expression of a rat brain serotonin transporter. Nature 354: 66-70, 1991.
8. Briscoe VJ, Ertl AC, Tate DB, Richardson AM, Davis SN. The effect of selective serotonin reuptake inhibitors (SSRI) on counterregulatory responses to hypoglycemia (Abstract). J Am Diabetes Assoc 55: A15, 2006.
9. Clouse RE, Lustman PJ, Freedland KE, Griffith LS, McGill JB, Carney RM. Depression and coronary heart disease in women with diabetes. Psychosom Med 65: 376-383, 2003.
10. Dagogo-Jack SE, Craft S, Cryer PE. Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest 91: 819-828, 1993.
11. Deeg M, Lipkin E. Hypoglycemia associated with the use of fluoxetine. West J Med 164: 262-263, 1996.
12. Erenmemisoglu A, Ozdogan UK, Saraymen R, Tutus A. Effect of some antidepressants on glycaemia and insulin levels of normoglycaemic and alloxan-induced hyperglycaemic mice. J Pharm Pharmacol 51: 741-743, 1999.
13. Evans MI, Halter JB, Porte D. Comparison of double- and single-isotope enzymatic derivative methods for measuring catecholamines in human plasma. Clin Chem 24: 567-570, 1978.
14. Evans SB, Wilkinson CW, Bentson K, Gronbeck P, Zavosh A, Figlewicz DP. PVN activation is suppressed by repeated hypoglycemia but not antecedent corticosterone in the rat. Am J Physiol Regul Integr Comp Physiol 281: R1426-R1436, 2001.
15. Goodnick P. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann Clin Psychiatry 13: 31-41, 2001.
16. Goodnick P, Henry J, Buki V. Treatment of depression in patients with diabetes mellitus. J Clin Psychiatry 56: 128-136, 1995.
17. Heisler LK, Kanarek RB, Gerstein A. Fluoxetine decreases fat and protein intakes but not carbohydrate intake in male rats. Pharmacol Biochem Behav 58: 767-773, 1997.
18. Holzwarth M, Brownfield M. Serotonin coexists with epinephrine in rat adrenal medullary cells. Neuroendocrinology 41: 230-236, 1985.
19. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71: 533-554, 2002.
20. Jensen JB, Jessop DS, Harbuz MS, Mork A, Sanchez C, Mikkelsen JD. Acute and long-term treatments with the selective serotonin reuptake inhibitor citalopram modulate the HPA axis activity at different levels in male rats. J Neuroendocrinol 11: 465-471, 1999.
21. Konkle AT, Bielajew C. Feeding and reward interactions from chronic paroxetine treatment. Pharmacol Biochem Behav: 435-440, 1999.
22. Korte SM, Van Duin S, Bouws GA, Koolhhaas JM, Bohus B. Involvement of hypothalamic serotonin in activation of the sympathoadrenomedullary system and hypothalamo-pituitary-adrenocortical axis in male Wistar rats. Eur J Pharmacol 197: 225-228, 1991.
23. Levkovitz Y, Shushan-Ben G, Hershokovitz A, Isaac R, Gil-Ad I, Shvartsman D, Ronen D, Weizman A, Zick Y. Antidepressants induce cellular insulin resistance by activation of IRS-1 kinases. Mol Cell Neurosci 36: 305-312, 2007.
24. Lucki I, Kreider MS, Simansky KJ. Reduction of feeding behavior by the serotonin uptake inhibitor sertraline. Psychopharmacology: 289-295, 1988.
25. Lustman P, Anderson R, Freedland K, De Groot M, Carney R, Clouse R. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 23: 934-942, 2000.
26. Lustman P, Clouse R. Treatment of depression in diabetes: impact on mood and medical outcome. J Psychosom Res 53: 917-924, 2002.
27. Lustman P, Clouse R, Nix B, Freedland K, Rubin E, McGill J, Williams M, Gelenberg AJ, Ciechanowski P, Hirsch I. Sertraline for prevention of depression recurrence in diabetes mellitus. Arch Gen Psychiatry 63: 521-529, 2006.
28. Lustman P, Freedland K, Griffith L, Clouse R. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care 23: 618-623, 2000.
29. Lustman P, Griffith L, Gavard J, Clouse R. Depression in adults with diabetes. Diabetes Care 15: 1631-1639, 1992.
30. Maekawa F, Toyoda Y, Torii N, Miwa I, Thompson RC, Foster DL, Tsukahara S, Tsukamura H, Maeda K. Localization of glucokinase-like immunoreactivity in the rat lower brain stem: for possible location of brain glucose-sensing mechanisms. Endocrinology 141: 375-384, 2000.
31. Maheux P, Ducros F, Bourque J, Garon J, Chiasson JL. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. Int J Obes Relat Metab Disord 21: 97-102, 1997.
32. Massand P, Gupta S. Selective serotonin-reuptake inhibitors: an update. Harv Rev Psychiatry 7: 69-84, 1999.
33. Mikkelsen JD, Hay-Schmidt A, Kiss A. Serotonergic stimulation of the rat hypothalamo-pituitary adrenal axis: interaction between 5-HT1A and 5-HT2A receptors. Ann NY Acad Sci 1018: 65-70, 2004.
34. Moore MC, DiCostanzo CA, Dardevet D, Lautz M, Farmer B, Neal DW, Cherrington AD. Portal infusion of a selective serotonin reuptake inhibitor enhances hepatic glucose disposal in conscious dogs. Am J Physiol Endocrinol Metab 287: E1057-E1063, 2004.
35. Moore MC, Geho WB, Lautz M, Farmer B, Neal DW, Cherrington AD. Portal serotonin infusion and glucose disposal in conscious dogs. Diabetes 53: 14-20, 2004.
36. Moore MC, Kimura K, Shibata H, Honjoh T, Saito M, Everett CA, Smith MS, Cherrington AD. Portal 5-hydroxytryptophan infusion enhances glucose disposal in conscious dogs. Am J Physiol Endocrinol Metab 289: E225-E231, 2005.
37. Neumaier JF, Root DC, Hamblin MW. Chronic fluoxetine reduces serotonin transporter mRNA and 5-HT1b mRNA in a sequential manner in the rat dorsal raphe nucleus. Neuropsychopharmacology 15: 515-522, 1996.
38. Rasmussen DD, Boldt BM, Bryant CA, Mitton DR, Larsen SA, Wilkinson CW. Chronic daily ethanol and withdrawal: 1. Long-term changes in the hypothalamo-pituitary-adrenal axis. Alcohol Clin Exp Res: 1836-1849, 2000.
39. Ritter S, Bugarith K, Dinh TT. Immunotoxic destruction of distinct catecholamine subgroups produces selective impairment of glucoregulatory responses and neuronal activation. J Comp Neurol 432: 197-216, 2001.
40. Ritter S, Dinh TT, Zhang Y. Localization of hindbrain glucoreceptive sites controlling food intake and blood glucose. Brain Res 856: 37-47, 2000.
41. Rosenthal MJ, Fajardo M, Gilmore S, Morley JE, Naliboff BD. Hospitalization and mortality of diabetes in older adults. A 3-year prospective study. Diabetes Care 21: 231-235, 1998.
42. Sanders NM, Figlewicz DP, Taborsky GJ Jr, Wilkinson CW, Daumen W, Levin BE. Feeding and neuroendocrine responses after recurrent insulin-induced hypoglycemia. Physiol Behav 87: 700-706, 2006.
43. Sawka AM, Burgart V, Zimmerman D. Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors. Diabetes Care 24: 1845-1846, 2001.
44. Schroeter S, Levey A, Blakely R. Polarized expression of the antidepressant-sensitive serotonin transporter in epinephrine-synthesizing chromaffin cells of the rat adrenal gland. Mol Cell Neurosci 9: 170-184, 1997.
45. Shores M, Pascualy M, Lewis N, Flatness D, Veith R. Short-term sertraline treatment suppresses sympathetic nervous system activity in healthy human subjects. Psychoneuroendocrinology 26: 433-439, 2001.
46. Smith GP, Epstein AN. Increased feeding in response to decreased glucose utilization in the rat and monkey. Am J Physiol 217: 1083-1087, 1969.
47. Strack A, Sawyer W, Platt K, Loewy A. CNS cell groups regulating the sympathetic outflow to adrenal gland as revealed by transneuronal cell body labeling with pseudorabies virus. Brain Res 491: 274-296, 1989.
48. Tjurmina OA, Armando I, Saavedra JM, Goldstein DS, Murphy DL. Exaggerated adrenomedullary response to immobilization in mice with targeted disruption of the serotonin transporter gene. Endocrinology 143: 4520-4526, 2002.
49. Turtle J, Burgess J. Hypoglycemic actions of fenfluramine in diabetes mellitus. Diabetes 22: 858-867, 1973.
50. Wilkinson CW, Raff H. Comparative evaluation of a new immunoradiometric assay for corticotropin. Clin Chem Lab Med 44: 669-671, 2006.